ArticleJournal of Cancer2019

EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions.

Yujie Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.